ClinicalTrials.gg

TargetBeta

CDK6

cyclin dependent kinase 6 · also PLSTIRE · Cyclin dependent kinases

7 programs in company-led studies act on CDK6, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
abemaciclibruleEli Lillyphase 44914 runningCDK4NCIt
palbociclibrulePfizerphase 4364 runningCCND1, CDK4ChEMBL
trilaciclibrulePharmacosmosphase 4143 runningCDK4ChEMBL
culmerciclibSino Biopharmaceuticalphase 3115 runningCDK2, CDK4the company's pipeline
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 374 runningFLT3, JAK2the studies' text
narazaciclibruleHangzhou Hanx Biopharmaceuticalsphase 243 runningCDK4, NUAK1NCIt
vustanaciclibRegor Pharmaceuticalsphase 233 runningCDK2, CDK4a judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.